Shots:

• J&J acquires Momenta in all-cash transaction at a price of $52.50/ share- making a total deal value as $6.5B. The transaction is expected to be closed in H2’20
• The acquisition allows J&J to expand its portfolio for autoimmune diseases with the addition of Momenta’s Nipocalimab (M281) to its pipeline. In addition to nipocalimab- Janssen will acquire Momenta's pipeline of clinical and pre-clinical assets
• Janssen plans to retain Momenta's presence in Cambridge- Massachusetts which will increase J&J footprint and capabilities in the key innovation hub. Nipocalimab provides an opportunity for Janssen to deliver transformative treatments in autoantibody-driven autoimmune diseases

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Canva